Clorox (NYSE:CLX) Stock Gets Price Target Bump from UBS Group

Clorox (NYSE:CLX – Get Free Report) had its target price upped by equities research analysts at UBS Group from $91.00 to $96.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group‘s target price suggests a potential upside of 3.65% from the company’s current price.

A number of other research firms also recently commented on CLX. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $95.00 target price on shares of Clorox in a report on Monday, October 19th. Zacks Research downgraded Clorox from a “hold” rating to a “strong sell” rating in a report on Thursday, October 29th. JPMorgan Chase & Co. lowered their price target on Clorox from $95.00 to $83.00 and set an “underweight” rating for the company in a report on Monday, October 19th. Wells Fargo & Company upped their price target on Clorox from $85.00 to $90.00 and gave the company an “equal weight” rating in a research report on Tuesday. Finally, TD Cowen restated a “hold” rating on shares of Clorox in a research note on Tuesday. One research analyst has rated the stock with a Buy rating, twelve have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $93.64.

Check Out Our Latest Stock Report on CLX

Clorox Stock Up 3.0%

Shares of Clorox stock traded up $2.72 during trading on Tuesday, reaching $92.62. The company had a trading volume of 1,098,582 shares, compared to its average volume of 2,642,461. The company has a debt-to-equity ratio of 15.80, a quick ratio of 0.38 and a current ratio of 0.66. Clorox has a fifty-two week low of $79.12 and a fifty-two week high of $128.90. The firm’s fifty day moving average is $88.27 and its 200-day moving average is $99.92. The company has a market cap of $11.20 billion, a price-to-earnings ratio of 19.18, a price-to-earnings-growth ratio of 2.91 and a beta of 0.59.

Clorox (NYSE:CLX – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.48. The business had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.88 billion. Clorox had a return on equity of 522.23% and a net margin of 8.74%. The company’s revenue for the quarter was up 33.3% compared to the same quarter last year. During the same period last year, the firm earned $0.85 earnings per share. On average, analysts anticipate that Clorox will post 5.66 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLX. Ancora Advisors LLC acquired a new stake in Clorox in the second quarter worth $28,000. Avalon Trust Co bought a new stake in Clorox in the second quarter valued at $29,000. Markowski Investments acquired a new position in shares of Clorox during the second quarter valued at $30,000. Root Financial Partners LLC boosted its holdings in shares of Clorox by 83.8% during the first quarter. Root Financial Partners LLC now owns 318 shares of the company’s stock valued at $33,000 after acquiring an additional 145 shares during the period. Finally, Pension & Wealth Management Advisors Inc. bought a new position in shares of Clorox during the third quarter worth about $26,000. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox News Roundup

Here are the key news stories impacting Clorox this week:

  • Positive Sentiment: Quarterly results exceeded expectations. Clorox reported adjusted earnings of $1.55 per share, well above the $1.07 consensus estimate, while revenue rose 33.3% year over year to $1.91 billion, topping the $1.88 billion forecast. Clorox Surpasses Q1 Earnings and Revenue Estimates
  • Positive Sentiment: Margin recovery efforts are showing progress. Productivity gains, strategic pricing and anticipated savings from the GOJO integration are helping offset higher input costs, supporting management’s confidence in its recovery plans. Productivity Gains and Strategic Pricing Drive Margin Recovery
  • Positive Sentiment: Analyst sentiment improved. Evercore ISI upgraded Clorox from “underperform” to “in line” with a $99 price target, citing the new CEO’s turnaround experience and potential for earnings recovery. Evercore ISI Upgrades Clorox
  • Neutral Sentiment: Fiscal 2027 guidance was maintained. Clorox forecasts adjusted EPS of $5.70-$6.00 and revenue of $7.6 billion-$7.7 billion, broadly in line with analyst expectations. Clorox Reports Fiscal 2027 Results
  • Negative Sentiment: Cost inflation remains a key risk. Management expects rising input costs and margin pressures to push results toward the lower end of its EPS range, increasing the importance of pricing actions, productivity savings and the GOJO integration. Clorox Earnings Call Highlights Inflation and Margin Pressures

Clorox Company Profile

(Get Free Report)

The Clorox Company, founded in 1913 and headquartered in Oakland, California, is a consumer and professional products company. It began with household bleach and has expanded into a portfolio of brands serving cleaning, household, personal care, food, and professional markets.

Its brands include Clorox disinfecting and cleaning products, Pine-Sol cleaners, Liquid-Plumr drain care, Kingsford charcoal, Fresh Step and Scoop Away cat litter, Hidden Valley dressings and dips, Brita water filtration products, and Burt’s Bees personal care items.

See Also

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.